Abstract: The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.

Abstract: The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereor or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage.

Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.

Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.

Abstract: The disclosure provides compositions and methods relating to the treatment of pain, such as pain from rheumatoid arthritis. By creating conjugates of antibodies that target C5aR and siRNA's that target C5 expression, a dual mode therapeutic that targets two different aspects of C5's inflammatory signaling.

Abstract: Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.

Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.

Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.

Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.